Agouron and Roche jointly to develop anti-cancer agents Thymitaq and AG3340.
Executive Summary
AGOURON & ROCHE TO DEVELOP THYMITAQ, AG3340 CANCER DRUGS and collaborate on discovering other early-stage anti-cancer therapies, the companies announced June 20. Under the letter-of-intent stage agreement, the initial target enzyme of the collaboration will be cdk4 (cyclin dependent kinases).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth